Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best healthcare stocks under $50 to invest in. TD Cowen maintained a ...

Roivant Sciences unveiled "exceptional" results Friday for its skin disease treatment, sending the biotech stock flying.

Roivant Sciences ROIV stock surged on Friday on positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS), an ...

Roivant Sciences (ROIV) upgraded to Buy on strong Phase 2 BEACON data for brepocitinib; see pipeline upside, risks, and why it’s timely—read now.

Roivant Sciences (NASDAQ:ROIV) executives highlighted new Phase II results for brepocitinib in cutaneous sarcoidosis, along ...

Roivant Sciences (ROIV) is up ~110% in 6 months, but still has no product revenue. Read here for a detailed investment analysis.

Roivant Sciences (NASDAQ:ROIV) will release its quarterly earnings report on Thursday, 2025-05-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Roivant Sciences ...

Shares of Roivant Sciences were higher after the company released positive results from a phase-two study of its brepocitinib treatment for cutaneous sarcoidosis, a skin disease. The stock rose 14% to ...

Roivant and Priovant Therapeutics announced positive results from a phase 3 study of brepocitinib. The drug could have blockbuster potential in treating rare and orphan autoimmune diseases. Shares of ...

As of Friday, February 06, Roivant Sciences Ltd.’s ROIV share price has surged by 17.48%, which has investors questioning if this is right time to sell.